Application Note: The new era of bispecific antibodies for cancer immunotherapy
Monoclonal antibodies have revolutionized cancer therapy since their introduction as therapeutics in the field. To enhance the specificity and potency of antibodies, bispecific antibodies (bsAbs) are emerging, with the ability to bind two different antigens or two different epitopes on the same antigen. More than 85% of bsAbs in clinical trials are cancer therapeutics.
In this Application Note, Sino Biological explores emerging bispecific antibodies and their targets in cancer immunotherapy in the discovery, development, preclinical and clinical stages.
The New Era of Bispecific Antibodies for Cancer Immunotherapy_Sino Biological_compressed
This content was provided by
